Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Veterinary Vaccine Import to Russia (Q1 2020)

Monday, April 27, 2020

Between January and March 2020, Russia imported 2.1 bln RUB worth of veterinary vaccines (customs clearance prices), which is in monetary terms (rubles) 8.4% lower than that of the same period in 2019. The dynamics in physical terms (units) are as low as -24.8%, or, if calculated in dosages, 13.5%. The import volume amounts to 1.13 mln units, or around 10.16 bln dosages.

The dynamics depended on the vaccine type. The import of combined vaccines had the lowest dynamics in monetary terms, -19.6%. However, the import volume was rather low, 120 mln RUB, which is less than 6% of the total import. The import of live and inactivated vaccines fell at about the same pace, with the dynamics of -7.9% and -7.3% in monetary terms. Live vaccines account for 50% of the import in monetary terms, while inactivated ones for 44%.

The difference is far more prominent in physical terms (dosages). Live vaccines account for 97.5% of the import, inactivated ones for around 2.5%, and combined for less than 0.01%. The dynamics of the import of inactivated vaccines are +220%, those of the import of live ones are -15%, and -43% for combined ones.

Only 10 companies imported live vaccines to Russia in Q1 2020. Biovac (Israel) and Eli Lilly (USA) have the highest dynamics in monetary terms (imports grown by 3.8 and 3.4 times, respectively). Biovac imported Vir vaccines for avian infectious bronchitis and virulent Newcastle disease, while Eli Lilly imported their Avipro vaccines, mostly for infectious bursal disease, chicken anaemia virus, and salmonellosis.

As for inactivated vaccines, there were 14 companies. Daesung Microbiological Labs (South Korea) has the highest dynamics, the company’s imports have grown by 3.7 times in monetary terms. It imported only Circo Pigvac, vaccine for porcine circovirus infection.

Among the four companies that imported combined vaccines to Russia in Q1 2020, only Boehringer Ingelheim had positive dynamics. The company’s imports (dog vaccine Eurican) have grown by 2.6 times.

Dynamics of veterinary vaccine import to Russia, free circulation prices (customs clearance included), 2015 – 2019, Q1 2020, bln RUB